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ABSTRACT
Introduction Vision impairment (VI) places a burden on 
individuals, health systems and society in general. In order 
to support the case for investing in eye health services, 
an updated cost of illness study that measures the global 
impact of VI is necessary. To perform such a study, a 
systematic review of the literature is needed. Here we 
outline the protocol for a systematic review to describe 
and summarise the costs associated with VI and its major 
causes.
Methods and analysis We will systematically search 
in Medline (Ovid) and the Centre for Reviews and 
Dissemination database which includes the National Health 
Service Economics Evaluation Database. No language 
or geographical restriction will be applied. Additional 
literature will be identified by reviewing the references in 
the included studies and by contacting field experts. Grey 
literature will be considered. The review will include any 
study published from 1 January 2000 to November 2019 
that provides information about costs of illness, burden 
of disease and/or loss of well- being in participants with 
VI due to an unspecified cause or due to one of the seven 
leading causes globally.
Two reviewers will independently screen studies and 
extract relevant data from included studies. Methodological 
quality of economic studies will be assessed based on the 
British Medical Journal checklist for economic submissions 
adapted to costs of illness studies. This protocol has been 
prepared following the Preferred Reporting Items for 
Systematic Reviews and Meta- Analysis protocols and has 
been published prospectively in Open Science Framework.
Ethics and dissemination Formal ethical approval is 
not required, as primary data will not be collected in this 
review. The findings of this study will be disseminated 
through peer- reviewed publications, stakeholder meetings 
and inclusion in the ongoing Lancet Global Health 
Commission on Global Eye Health.
Registration details https:// osf. io/ 9au3w (DOI 10.17605/
OSF.IO/6F8VM).
BACKGROUND
Vision impairment (VI) is a major public 
health issue. In 2015 an estimated 36 million 
people (80% uncertainty interval 12.9–65.4) 
were blind (visual acuity worse than 3/60 in 
the better eye) and 216.6 million (80% uncer-
tainty interval 98.5–359.1) were moderately 
or severely visually impaired (visual acuity 
better than 3/60 but worse than 6/18 in the 
better eye).1 In 2015, 87% of blindness and 
75% of moderate and severe VI was due to 
seven causes—uncorrected refractive error, 
cataract, glaucoma, age- related macular 
degeneration (AMD), diabetic retinopathy, 
corneal opacity and trachoma.2
VI—being the combination of blindness 
and moderate and severe VI—is associated 
with a range of consequences including diffi-
culties performing activities of daily living,3–5 
reduced mobility,6 higher risk of depres-
sion,7 8 reduced educational outcomes,9 
impaired workplace productivity,10 decreased 
Strengths and limitations of this study
 ► This protocol adheres to the Preferred Reporting 
Items for Systematic Reviews and Meta- Analysis 
protocols and has been published prospectively in 
Open Science Framework.
 ► This systematic review will search various databas-
es extensively and will include studies published 
from 1 January 2000 to November 2019 without any 
language or geographical restriction.
 ► All included studies will be appraised using the 
British Medical Journal checklist for economic sub-
missions adapted for the cost of illness studies.
 ► Synthesis of findings will be difficult as resource use 
(including diagnostic procedures and treatment op-
tions) and costs will likely vary between countries, 
over time and according to which cause(s) of vision 
loss is reported—in lieu of synthesis, we will sum-
marise the range and quality of available evidence, 
and the subsequent gaps where evidence should be 
produced and improved.
 ► Due to the expected heterogeneity in study methods, 
it is unlikely that a meta- analysis will be conducted.
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quality of life,11 increased risk of falls,12 higher levels of 
dependency,3 increased need for informal and formal 
care,13–15 and an increased need for healthcare.16–18 All 
of these lead to an economic burden for individuals, 
health systems and society. VI may occur at any age due to 
genetic, acquired or trauma- related causes. However, the 
prevalence of VI increases with age in all world regions.
In 2010, the only global estimate for the cost of VI 
conducted to date reported a cost of US$2954 billion,19 
with direct costs of US$2302 billion and informal care 
costs of US$246 million.19 This analysis included produc-
tivity losses for high- income countries only, and in 2010 
these were estimated to be US$168.3 billion.19
Another estimate of productivity losses due to VI has 
been reported in a study that used data from nine coun-
tries from high- income, middle- income and low- income 
countries and three different analysis approaches.20 
The most conservative of these approaches estimated 
that productivity losses due to VI in 2011 ranged from 
US$0.1 billion in Honduras to US$7.8 billion in USA.20 
The authors concluded that although VI occurs more 
frequently in low- income and middle- income countries, 
the economic burden is still substantial in high- income 
countries, such as USA and Japan.20 Further, the full cost 
of VI is conceivably much higher if direct and informal 
care costs were included in estimates.
In order to make a case for investment and to develop 
plans to alleviate the burden of VI, an updated cost 
of illness study measuring the global impact from an 
economic and societal perspective is necessary.
Cost of illness studies measure the economic burden 
of a disease or condition on the overall population.21 22 
They are descriptive and analytic studies that estimate 
all direct healthcare costs, productivity losses and intan-
gible costs of a disease or illness.23 They are conducted to 
advise healthcare planners about the size of a problem in 
a population, to update and support policy and financing 
decisions and to inform full economic evaluation studies, 
namely cost- effectiveness and cost–benefit analyses.24 25 
Cost of illness studies do not compare alternative inter-
ventions and as such are considered partial economic 
evaluation studies.26 27
To perform a global cost of illness study, all available 
data must be identified and collated in a structured way. 
In 2012, a systematic review was conducted to inform a 
cost of illness study on VI and main causes of VI in high- 
income countries and a total of 22 studies were identified 
that reported direct and/or indirect costs related to VI.28 
Since 2012, new treatments (eg, anti- vascular endothelial 
growth factor (anti- VEGF) therapy) and technologies (eg, 
ocular imaging) have emerged. These are expected to 
increase direct costs and, if effective, improve outcomes.
A new systematic review is now required for three 
reasons. First, the search will be extended to include low- 
income and middle- income as well as high- income coun-
tries to allow comprehensive global estimates. Second, 
we will expand the search to include the seven major 
causes of VI identified in the latest global prevalence 
estimates—cataract, uncorrected refractive error, diabetic 
retinopathy, glaucoma, AMD, corneal opacity and 
trachoma.2 Finally, a new systematic review will capture 
studies on new treatments, such as anti- VEGF treatment, 
which may result in both substantial costs and savings, 
and are thus likely to affect the societal cost of VI.
PURPOSE
The aim of this systematic review is to describe and 
summarise the costs associated with VI and its major 
causes.
METHODS AND ANALYSIS
The protocol is reported in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta- Analysis 
protocols (PRISMA- P) checklist29 30 (online supplemen-
tary annex 1) and has been registered previously in Open 
Science Framework.
Search
Literature searches will be performed in Medline (Ovid) 
and the Centre for Reviews and Dissemination database 
which includes the National Health Service Economics 
Evaluation Database, Database of Abstracts of Reviews 
of Effects and the Health Technology Assessment data-
base. Searches will be run to identify studies published 
from 1 January 2000 to November 2019, and no language 
or geographical restrictions will be applied. The search 
strategy is provided in online supplementary annex 2.
The reference lists of included articles will be reviewed 
for additional relevant articles. Field experts, including 
health economists and eye care researchers who have 
conducted economic evaluation in eye care will be 
contacted to identify further potentially relevant studies 
and reports in the grey literature. These individuals will 
be identified from the authorship of the identified arti-
cles and snowballing via recommendations from Commis-
sioners in the Lancet Commission on Global Eye Health.
Criteria
Studies will be included if they:
 ► are partial economic evaluation studies such as cost 
of illness studies, burden of illness/diseases and full 
economic evaluation studies such as cost- effectiveness 
and cost–benefit studies published since 1 January 
2000; and
 ► report in the results section a monetary estimate of 
the direct and/or indirect and/or productivity and/
or informal care costs associated with persons with 
VI from an unspecified cause or due to one of the 
seven leading causes of vision loss globally (ie, cata-
ract, uncorrected refractive error, diabetic retinop-
athy, glaucoma, AMD, corneal opacity and trachoma); 
and/or
 ► report at least one of:
 – undiscounted or discounted cost or benefit results; 
and/or
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 – an estimate of the impact of VI on labour mar-
ket outcomes (eg, employment chances, labour 
income, wages and lost work days), informal care 
(eg, number of caregiver hours) or in terms of well- 
being (eg, Quality Adjusted Life Years (QALYs), 
Disability Adjusted Life Years (DALYs).
Studies will be excluded if they:
 ► only report incremental costs, net costs, incremental 
benefits or net benefits, incremental cost- effectiveness 
ratio, incremental cost–benefit ratios without also 
reporting actual costs; or
 ► report costs and benefits related to specific eye 
diseases that are not one of the seven leading causes 
of vision loss globally; or
 ► report costs of services for people with one of the major 
causes of VI (eg, screening for everyone with diabetic 
retinopathy, providing medication for everyone with 
glaucoma) without specifically reporting the costs 
to deliver the service to people with VI. The excep-
tions will be studies reporting costs of services to treat 
cataract and refractive error—these will be included 
regardless of the vision status of participants, as they 
tend to be single (for cataract) or irregular (for refrac-
tive error) interventions that correct the VI, compared 
with the services required for the other causes; or
 ► are reviews of existing economic studies related to VI; 
or
 ► report an economic model based on other studies, 
but do not report any primary costs data.
Inclusion criteria are summarised and complemented 
with PICOS details in table 1.
Methodological features of cost of illness studies
Cost of illness studies follow two different epidemiolog-
ical approaches: prevalence- based or incidence- based 
approaches.21 31 Prevalence- based studies estimate costs 
associated with prevalent cases over a given period of time 
(usually 1 year), while incident- based studies estimate 
costs accrued over a lifetime following the onset of the 
illness or loss of health state.
Cost of illness studies can be conducted from various 
perspectives, including societal, governmental, healthcare 
system, payer, healthcare provider and patient.21 The 
analysis approach varies with the chosen perspective and 
may include direct costs, productivity costs, informal care 
costs and intangible costs.25 32
Direct costs may include direct medical and non- medical 
costs associated with inpatient and outpatient care and 
all the resources used for diagnosis and treatment of 
eye disease and its sequelae, long- term care and nursing 
home costs, community care and paid assistance provided 
by professionals, costs related to vision aids and devices 
and home modifications and transportation costs to 
access services. Productivity costs (formerly called indirect 
costs) may include absenteeism, presenteeism, reduced 
workforce participation and lost productivity due to 
premature mortality. Informal care may include hours 
spent by caregivers and/or a monetary estimate of the 
hours spent in care. Intangible costs are captured through 
QALYs and DALYs. Transfer payments such as social welfare 
payments made for distributional purposes. Deadweight 
losses namely the cost to society of administering certain 
transfer payments, such as social welfare payments.
Resource consumption estimates depend largely on the 
characteristics of the available data21 32 and are usually 
categorised as top- down (‘population- level’) or bottom- up 
(‘person- based’).21 Top- down methods use aggregate 
expenditures by cost component while the bottom up 
method assigns costs to individuals with a specific disease 
or condition.
Selection of sources of evidence
All titles and abstracts will be screened by two investigators 
independently (APM and one of JR, JZ, ThB) using Covi-
dence systematic review software (Veritas Health Innova-
tion, Melbourne, Australia. Available at www. covidence. 
org). After completing the screening process, full texts will 
be assessed by two investigators independently to establish 
eligibility for inclusion into the study. Since formal interna-
tional guidelines for quality assessment of economic studies 
are lacking,33 all included studies will be appraised by two 
investigators independently using the British Medical Journal 
checklist34 for economic submissions adapted for cost of 
illness studies.25 Each quality criteria will be scored as one 
Table 1 Summary of the PICOS elements for the systematic review
Participants Participants with VI from an unspecified cause or due to one of the leading causes of VI globally (ie, 
cataract, uncorrected refractive error, diabetic retinopathy, glaucoma, AMD, corneal opacity and trachoma).
Interventions Any report that provides information about costs of illness, burden of diseases and/or loss of well- being in 
participants with VI or eye disease potentially leading to VI.
Comparators Not relevant
Outcomes Direct costs, indirect costs, productivity losses, informal care and intangible costs (eg, Quality Adjusted Life 
Years, Disability Adjusted Life Years), transfer payments and deadweight losses.
Study Design Partial economic evaluation studies such as cost of illness studies, burden of illness/diseases and full 
economic evaluation studies, such as cost- effectiveness and cost–benefit studies. Model- based economic 
evaluation studies not reporting any primary cost data or based on reviews of existing economic studies will 
be excluded.
AMD, age- related macular degeneration.
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of ‘yes’, ‘no’, ‘partial’ or ‘not applicable’. We will follow 
the approach used several times previously to identify the 
methodological strengths and weakness of the included 
studies32 35 36—equal weight will be assigned to each item of 
the checklist and the final score will be equal to the sum of 
the 10 individual items. Any conflict in relation to screening 
and appraisal will be discussed between the two investiga-
tors, and resolved with a third investigator if necessary. A 
PRISMA flow diagram will be completed to summarise the 
study selection process.
Data extraction characteristics
The following information will be extracted from the 
included studies:
 ► Country or countries of study.
 ► Study period.
 ► Study size (eg, population- based studies or sampled- 
based studies).
 ► Age range of participants.
 ► Study design (eg, cost of illness, burden of illness/
diseases, cost- effectiveness or cost–benefit studies).
 ► Epidemiological approach (eg, incidence- based or 
prevalence- based).
 ► Perspective of analysis (eg, societal, government, 
healthcare system, payer, healthcare provider or 
patient).
 ► Main data sources (eg, published expenditures report, 
administrative database, population survey, patient 
clinical records, patient diaries, specially designed 
questionnaires, published literature).
 ► Method of resource quantification (eg, top- down or 
bottom- up).
 ► VI definition and VI severity (eg, blind, moderate or 
severe VI).
 ► Cause of VI (and definition).
 ► Disease stage.
 ► Currency in which costs are reported.
 ► Cost components (eg, direct costs, productivity costs, 
informal care costs).
 ► Loss of well- being measures (eg, intangible costs 
measured with QALYs, DALYs, years of sight loss).
 ► Analysis of uncertainty (eg, type of uncertainty 
analysed (parameter uncertainty, methodological 
uncertainty or modelling uncertainty), choice of 
parameters included in sensitivity analysis, univariate 
sensitivity analysis, probabilistic sensitive analysis).
 ► Discounting methods (eg, discount rate applied and 
justification).
If the study perspective or the epidemiological approach 
is not clearly specified in the studies, two investigators will 
assign a category for it by consensus.
Synthesis of results
Selected studies will be characterised in terms of country 
of origin, epidemiological approach, perspective of anal-
ysis, study design, study size, methods of resource quanti-
fication and methods to deal with uncertainty.
We will describe the main reported cost categories and 
the general assumptions used to estimate costs. We will 
take four steps to prepare study results for comparison:
1. We will categorise studies either as ‘general’ studies 
that reported costs for people with blindness or VI or 
‘condition’-specific studies that reported costs for peo-
ple with one of the seven specified causes of vision loss.
2. If costs per patient per year are not reported for na-
tional or global estimates studies, these will be calculat-
ed for studies where sufficient information is provided.
3. Costs will be inflated to 2018 values (or to the most 
recent available year) using country- specific gross do-
mestic product deflators.37
4. Costs will be converted to USD purchasing power pari-
ties (PPP)38 to equalise the purchasing power of differ-
ent currencies.
Time transformations will adjust for inflation costs 
reported in the same country but in different years. Conver-
sion to USD PPP conversion will adjust for the same price 
level costs estimates reported in different countries and 
different currencies. This cost transformation will convert 
all reported costs to the same year (2018), same currency 
and same purchasing power (USD PPP).
Due to anticipated heterogeneity in the cost data, studies 
will be stratified and presented by the four different cost 
components (ie, direct costs, productivity losses, informal 
care and intangible costs), with a clear explanation of what 
has been included in each of the four cost components. 
A table summarising which items are included in the four 
major cost components will be reported to summarise the 
similarities and differences between studies. Cost data will 
also be stratified by severity of VI when this information is 
available. Since this systematic review aims to collect data to 
assist a future global economic estimate for VI and its major 
causes, the transformed cost per patient per year stratified 
by cost components will be aggregated by Global Burden of 
Diseases regions and super regions. Descriptive measures 
will be calculated to report the cost per patient per year for 
each region and super region (eg, mean, SD, minimum and 
maximum).
We will describe the main reported loss of well- being 
measures and its general assumptions. Loss of well- being 
measures will be summarised in their natural units (eg, 
QALYS and DALYS) rather than reported in their mone-
tised value since there is no consensus on assigning a mone-
tary value to health outcomes21 26 39 and because there is no 
common acceptable value across countries.
Due to the expected heterogeneity in study design, defi-
nitions of costs/loss of well- being,40 it is unlikely that a meta- 
analysis will be conducted.
ETHICS AND DISSEMINATION
Formal ethical approval is not required, as primary data will 
not be collected in this review. The findings of this study will 
be disseminated through a peer- reviewed publication, stake-
holder meetings and inclusion in the ongoing Lancet Global 
Health Commission on Global Eye Health.41
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PATIENT AND PUBLIC INVOLVEMENT
Patients and the public were not involved in the design of this 
systemic review protocol.
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